openPR Logo
Press release

Life-Saving Solutions: Doxorubicin Front and Center in Market Report 2024

06-03-2024 09:03 PM CET | Health & Medicine

Press release from: The Business Research Company

Life-Saving Solutions: Doxorubicin Front and Center in Market

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Doxorubicin Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $1.71 billion In 2028 At A CAGR Of 6.7%.

The doxorubicin market size has grown strongly in recent years. It will grow from $1.23 billion in 2023 to $1.32 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to chemotherapy advancements, oncology treatment standard, clinical efficacy, patient survival rates, physician recommendations.

The doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to personalized medicine advancements, targeted drug delivery systems, immunotherapy combinations, genomic and biomarker research, precision oncology growth. Major trends in the forecast period include nanotechnology integration, combination therapies, biosimilar market expansion, adjuvant therapy focus, cardioprotective interventions.

Request A Sample Of This Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=11974&type=smp

Doxorubicin Market Major Segments
The doxorubicin market covered in this report is segmented -

1) By Drug Formulation: Lyophilized Powder, Doxorubicin Injection
2) By Application: Breast Cancer, Kidney Cancer, Liver Cancer, Sarcoma, Ovarian Cancer, Lung Cancer, Leukemia, Multiple Myeloma, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Key Driver - Increasinng Cancer Cases Boost Doxorubicin Market

The increasing prevalence of cancer is driving the doxorubicin market forward. Cancer is a group of diseases in which cells grow abnormally and uncontrollably. Doxorubicin is a common antibiotic used in chemotherapy to treat distinct types of cancers, as it limits the growth of cancer cells by damaging their DNA. The growing incidence of cancer has led to a higher demand for doxorubicin. For instance, according to the 2021 American Cancer Society report, 1.8 million new cases of cancer diagnosed were diagnosed in 2020. Furthermore, according to September 2020 data published by the National Cancer Institute, a US-based government agency part of the National Institutes of Health, 1,806,590 new cancer cases were recorded, indicating that 43% of all cancer diagnosed in men in the United States in 2020, up from 1,752,735 in the previous year, i.e., 2019. Thus, the increasing prevalence of cancer patients is driving the doxorubicin market.

Customise This Report As Per Your Requirements -
https://www.thebusinessresearchcompany.com/Customise?id=11974&type=smp

Prominent Trend - Drug Innovation For Myeloma Treatment

Advancements in drug Investigation are a key trend gaining popularity in the doxorubicin market. Major companies in the doxorubicin market are working on innovative technologies to launch advanced products, such as injections, to sustain their position in the market. For instance, in October 2021, Padagis, a US-based healthcare company, received approval for its AB-rated generic version of Doxil (Doxorubicin Liposome Injection) from the US Food and Drug Administration, a US-based health regulatory agency. The new drug is an anthracycline topoisomerase inhibitor used for treating ovarian cancer, sarcoma, and multiple myeloma. It is also used in the treatment of multiple myeloma alongside bortezomib. Doxorubicin liposome is a cancer medication that acts as an antineoplastic agent.

Doxorubicin Market Players
Major companies operating in the doxorubicin market report are Pfizer Inc., Johnson and Johnson, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Hospira Inc., Dr. Reddy's Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals, Mylan Pharmaceuticals Inc., VHB Life Sciences Limited, Xi'an International Healthcare Factory Co. Ltd., Accord Healthcare Ltd., TTY Biopharm Company Limited, Cadila Pharmaceuticals, Neon Laboratories Limited, APP Pharmaceuticals Manufacturing LLC, Sun Pharmaceutical Industries Ltd., Transo-Pharm Handels GmbH, LGM Pharma, Zhejiang Hisun Pharma, Actavis Pharma, Celon Laboratories Limited, Samarth Life Sciences Pvt. Ltd

View The Full Report Here -
https://www.thebusinessresearchcompany.com/report/doxorubicin-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the doxorubicin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the doxorubicin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Doxorubicin Market Report Structure
3. Doxorubicin Market Trends And Strategies
4. Doxorubicin Market - Macro Economic Scenario
5. Doxorubicin Market Size And Growth
…..
27. Doxorubicin Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Life-Saving Solutions: Doxorubicin Front and Center in Market Report 2024 here

News-ID: 3523969 • Views:

More Releases from The Business Research Company

Emerging Trends to Reshape the Surgical Energy Instruments Market: Innovative Technologies In Surgical Energy Instruments as a Key Influencer
Emerging Trends to Reshape the Surgical Energy Instruments Market: Innovative Te …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. Surgical Energy Instruments Market Size Valuation Forecast: What Will the Market Be Worth by 2025? In the past few years, the market size of surgical energy instruments has seen substantial growth. The market which is projected to be worth $4.68 billion in 2024, is expected to inflate to $5.2
2025-2034 Spatial omics Market Evolution: Disruptions, Innovations, and Untapped Opportunities
2025-2034 Spatial omics Market Evolution: Disruptions, Innovations, and Untapped …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Is the Expected CAGR for the Spatial omics Market Through 2025? In recent years, the size of the spatial omics market has seen rapid expansion. The estimations show an increase to $0.33 billion in 2025 from $0.3 billion in 2024, marking a compound annual growth rate (CAGR) of
Global Sigmoidoscope Market Projected to Grow at 6.1% CAGR, Reaching $3.38 Billion by 2029
Global Sigmoidoscope Market Projected to Grow at 6.1% CAGR, Reaching $3.38 Billi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Sigmoidoscope Industry Market Size Be by 2025? In recent years, there has been a significant increase in the size of the sigmoidoscope market. The market is projected to expand from $2.53 billion in 2024 to $2.67 billion in 2025, demonstrating a compound annual growth rate (CAGR)
2025-2034 Refurbished MRI Systems Market Roadmap: Insights for Competitive Advantage
2025-2034 Refurbished MRI Systems Market Roadmap: Insights for Competitive Advan …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Refurbished MRI Systems Market Size By 2025? The market size for refurbished MRI systems has experienced robust growth in the past few years. It is expected to rise from $0.77 billion in 2024 to $0.85 billion in 2025, showcasing a compound annual growth rate (CAGR)

All 5 Releases


More Releases for Doxorubicin

Rising Prevalence Of Cancer Fuels Growth In Liposomal Doxorubicin Market: A Sign …
The Liposomal Doxorubicin Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Liposomal Doxorubicin Market Size and Projected Growth Rate? The liposomal doxorubicin market has also shown strong growth in recent years. It is expected to grow from $1.23 billion in 2024 to $1.32
Doxorubicin Market: Prospects for Long-Term Value & Growth
The "Global Doxorubicin" intelligence report, just published by USD Analytics, covers insurers' micro-level study of important market niches, product offers, and sales channels. In order to determine market size, potential, growth trends, and competitive environment, the Global Doxorubicin provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the study featured Johnson
Exploring the Doxorubicin Market: A Comprehensive Deep Dive
The Doxorubicin market has been on an impressive growth trajectory, largely propelled by the alarming surge in cancer cases across the globe. As of 2023, the market has already reached a substantial valuation of USD 1,218 million, and experts anticipate a promising future. Projections indicate a Compound Annual Growth Rate (CAGR) of 6.4% during the forecast period spanning from 2024 to 2032. This growth trajectory aims to achieve an astonishing
Liposomal Doxorubicin Market - Powerful Delivery, Enhanced Outcomes: Empowering …
Newark, New Castle, USA - new report, titled Liposomal Doxorubicin Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liposomal Doxorubicin market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liposomal Doxorubicin market. The report offers an overview of the market, which
12-14-2022 | Health & Medicine
Fact.MR
Doxorubicin Market Value Projected to Expand by 2032
From 2022 to 2026, demand for doxorubicin is expected to rise at a 5.3% CAGR. The global doxorubicin market is currently valued at US$ 1.1 billion and is expected to reach US$ 1.3 billion by the end of 2026. Doxorubicin shipments in Japan and Canada are expected to rise at CAGRs of 3.9% and 5.3%, respectively, through 2026. 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.factmr.com/connectus/sample?flag=S&rep_id=7303 Analysts aim to provide a
Global Doxorubicin Market Insights, Forecast
Doxorubicin is a kind of antitumor antibiotics, can inhibit the synthesis of RNA and DNA, RNA in the strongest inhibitory effect. Doxorubicin has an effect on a wide variety of tumor, belongs to the cycle non-specific drug, have all sorts of growth cycle of tumor cells to kill.it's given by injection into a vein. The global Doxorubicin market is valued at 910 million US$ in 2018 and will reach 1410